clinical trial · NCT05755997
CERebrolysin In CADASIL
CadasilCerebrolysin0.9 % NaCl
brief summary
The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to Placebo in patients with genetically proven CADASIL. In addition, a traditional approach will be taken based on an evaluation of the separate risk and benefit domains in comparison with placebo.
started
Nov 29, 2023
primary completion
Mar 31, 2026
completion
Dec 31, 2026
last updated
Feb 25, 2025
detailed description
Safety data area collected throughout the study (adverse events, vital signs and laboratory tests) and thereafter in case of ongoing serious adverse events (SAEs) at study endpoint.
Optional secondary parameters include analyses of biomarkers (samples of blood, hair, urine, and saliva).
official title
A Randomized, Double-blind, Single-centre, Two-period Cross-over, Placebo-controlled Trial on Safety and Efficacy in Patients With Genetically Proven CADASIL
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol